BRUSSELS/LONDON, Sept 26 (Reuters) - UCB, fresh from a deal to buy Germany's Schwarz Pharma (SRZG.DE: Quote, Profile, Research), reported positive clinical trial results with two new epilepsy medicines on Tuesday but a minor delay for a drug against lupus.
